Time on boards
- Boards served
- 4
- Current seats
- 4
- Board service
- 15 years
- Director since
- 2023
15 years of board service in total across 4 boards, counting each seat separately. Longest: Becton Dickinson and Company, 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
QUALCOMM Incorporated March 17, 202695.0%
-
Becton Dickinson and Company January 27, 202697.7%
-
Halozyme Therapeutics Inc. May 1, 202596.8%
-
QUALCOMM Incorporated March 18, 202597.0%
-
Becton Dickinson and Company January 28, 202591.2%
-
QUALCOMM Incorporated March 5, 202493.8%
-
Becton Dickinson and Company January 23, 202491.0%
-
QUALCOMM Incorporated March 8, 202392.7%
-
Becton Dickinson and Company January 24, 202387.2%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 5, 2026 | Halozyme Therapeutics Inc. | Grant or award | +3,796 | — | — |
| Mar 17, 2026 | QUALCOMM Incorporated | Grant or award | +2,563 | — | — |
| Mar 8, 2026 | QUALCOMM Incorporated | Option exercise | +2,355 | — | — |
| Mar 8, 2026 | QUALCOMM Incorporated | Sold back to the company | −759 | $135.69 | $102,989 |
| Jan 27, 2026 | Becton Dickinson and Company | Grant or award | +1,098 | — | — |
| May 1, 2025 | Halozyme Therapeutics Inc. | Grant or award | +4,165 | — | — |
| Apr 28, 2025 | Halozyme Therapeutics Inc. | Open-market sale | −4,297 | $60.34 | $259,281 |
| Apr 28, 2025 | Halozyme Therapeutics Inc. | Open-market sale | −200 | $61.00 | $12,200 |
| Apr 1, 2025 | Halozyme Therapeutics Inc. | Open-market sale | −503 | $64.05 | $32,217 |
| Mar 18, 2025 | QUALCOMM Incorporated | Grant or award | +2,097 | — | — |
| Mar 9, 2025 | QUALCOMM Incorporated | Option exercise | +1,901 | — | — |
| Mar 3, 2025 | Halozyme Therapeutics Inc. | Open-market sale | −1,795 | $57.93 | $103,984 |
| Mar 3, 2025 | Halozyme Therapeutics Inc. | Open-market sale | −3,205 | $59.12 | $189,480 |
| Feb 10, 2025 | Becton Dickinson and Company | Open-market purchase | +1,500 | $233.62 | $350,430 |
| Feb 3, 2025 | Halozyme Therapeutics Inc. | Open-market sale | −1,100 | $55.94 | $61,534 |
Questions about Jeffrey William Henderson
What boards is Jeffrey William Henderson on?
Jeffrey William Henderson sits on the boards of Becton Dickinson and Company, Halozyme Therapeutics Inc., Kyntra Bio Inc. and QUALCOMM Incorporated.
How long has Jeffrey William Henderson served on boards?
Our records show at least 15 years of board service across 4 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.